Journal of Advances in Medical and Pharmaceutical Sciences

In present research work, we have developed ileo-colonic targeted matrix tablets of flurbiprofen for chronotherapeutic treatment of ulcerative colitis. Direct compression technique was used to formulate matrix tablets of flurbiprofen using microsomal enzyme dependent and pH-sensitive polymers. FTIR and DSC studies were conducted to access the compatibility for flurbiprofen, polymers and physical mixtures. In this research we have used two types of polymer one is synthetic and other is natural, and both polymers have achieving colon targeted drug A physicochemical study was evaluated of all formulated batches. Estimation of drug content, in vitro release of drug and stability studies was also performed. No interaction was observed between drug and the polymers in FTIR and DSC studies. However when the formulated matrix tablets were subject to physicochemical properties then all the readings were within limits. The percentage of flurbiprofen in the optimized formulation C5 was found to be 98±0.10%. According to the guide-lines of International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use the formulation was found to be stable. Six formulations were prepared and evaluate. For the protection of drug from the environment of the stomach pH dependent polymers Eudragit S100 was used for its enteric coating.